New CAR t therapy targets Hard-to-Treat ovarian cancers

NCT ID NCT06469281

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests an experimental treatment called 27T51, a type of immune cell therapy (CAR T) designed to attack cancer cells that carry a protein called MUC16. The study includes about 90 women with ovarian, peritoneal, or fallopian tube cancer that has come back or is hard to treat. The goal is to find a safe dose and see if the therapy can shrink tumors, possibly combined with other drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Show contact details

Locations

John Theurer Cancer Center Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
LDS Hospital
RECRUITING

Salt Lake City, Utah, 84143, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14203, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.